UroToday.com – An article in the online edition of Cancer assesses differences in prostate cancer (CaP) treatment, trust and regular patient care based upon patient race. The North Carolina-Louisiana prostate Cancer Project (PCaP) is a population-based study of men identified shortly after CaP diagnosis. Enrollment began in 2004, however there was a temporary study enrollment lapse in Louisiana...

UroToday.com – An article in the online edition of Cancer assesses differences in prostate cancer (CaP) treatment, trust and regular patient care based upon patient race. The North Carolina-Louisiana prostate Cancer Project (PCaP) is a population-based study of men identified shortly after CaP diagnosis. Enrollment began in 2004, however there was a temporary study enrollment lapse in Louisiana...

Schering-Plough Corp. (NYSE: SGP) announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter to the company’s supplemental Biologics License Application regarding PEGINTRON® (pegylated interferon alfa-2b) for the adjuvant treatment of patients with stage III malignant melanoma after complete lymphadenectomy. Schering-Plough will work closely with FDA to respond...

Targeted immunotherapy has been an attractive new therapeutic area for a number of cancers because it has the potential to destroy tumor cells without damaging surrounding normal tissue. New study results demonstrate high success rates using specialized white blood cells to prevent or treat lymphoma associated with the Epstein-Barr virus (EBV-lymphoma) in patients who have received a hematopoietic...

Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) reported that it has completed enrollment in the REVEAL-1 (Response Evaluation of VorEloxin in AmL) trial, a Phase 2 dose regimen optimization trial of single agent voreloxin in newly diagnosed elderly acute myeloid leukemia (AML) patients who are unlikely to benefit from standard induction chemotherapy. A total of 113 patients were enrolled and dosed according...

Researchers at UT Southwestern Medical Center have eliminated non-small cell lung (NSCL) cancer in mice by using an investigative drug called BEZ235 in combination with low-dose radiation. Read Full Article

Eisai Inc. announced preliminary results from a recently completed Phase III study with eribulin mesylate (E7389), discovered and developed by the company, in patients with locally advanced or metastatic breast cancer. Read Full Article

A new, innovative form of radiation based on verified scientific facts will be available to patients all over Europe within the next few decades. The official kick-off meeting of the Community project ULICE (Union of LIght Ions Centres in Europe), which the European Union supported with nearly 10 million euros, was held in the fall of 2009 in the Department of Radiooncology and Radiation Therapy of...

Like yoga for office drones, cells do have coping strategies for stress. Heat, lack of nutrients, oxygen radicals – all can wreak havoc on the delicate internal components of a cell, potentially damaging it beyond repair. Proteins called HSPs (heat shock proteins) allow cells to survive stress-induced damage. Scientists have long studied how HSPs work in order to harness their therapeutic potential. Read...

The European Medicines Agency has been formally notified by AstraZeneca of its decision to withdraw its application for a centralised marketing authorisation for the medicine Zactima (vandetinib), 100 mg film-coated tablets. Zactima was expected to be used in combination with chemotherapy, for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have...